CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$26.27
1.69 (6.88%)
▲
5d:
+20.5%
30d:
+67.86%
90d:
+64.81%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CAI is 18.8% above its trading range ($22.11). Market expects 12.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CAI is 18.8% above its trading range ($22.11). Market expects 12.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.40
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.42
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $26.27, which is considered extended relative to its 30-day fair value range of $15.32 to $22.11. From a valuation perspective, the stock is trading at a premium (Forward PE: 69.5) compared to its historical average (49.2). At these levels, the market is pricing in 12.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAI is showing sideways momentum. The price is approaching resistance at $26.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: CAI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAI is showing sideways momentum. The price is approaching resistance at $26.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: CAI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.32 -
$22.11
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
18.1%
All Signals
- BEARISH: Price significantly overextended (+18.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.9%)
- NEUTRAL: Near Wall St target ($27.00)
- NEUTRAL: Trading at premium valuation - market expects 12.2% growth which is achievable
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$15.32 -
$22.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$20.78
Resistance Level
$26.60
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
69.52
Wall Street Target
$27.00
(+2.8%)
Revenue Growth (YoY)
45.4%
Profit Margin
10.6%
Valuation Premium vs History
+12.2% premium
PE vs Historical
69.5 vs 49.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.2%
(market-implied from PE analysis)
1-Year Target
$29.47
(+12%)
2-Year Target
$33.07
(+26%)
3-Year Target
$37.11
(+41%)
3-Yr Target (if PE normalizes)
(PE: 70→49)
PE COMPRESSION
$26.26
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 69.5, Growth: 162.2%)
$88.66
(+238%)
Base:
(SPY PE: 20.1, Growth: 162.2%)
$25.60
(-3%)
Bear:
(PE: 17.1, Growth: 162.2%)
$21.76
(-17%)
📈
Valuation based on Current Earnings
Trailing PE: 2.38 | Current EPS (TTM): $10.34
Bull Case
$13.52
(-49%)
Analyst growth -50.0%, PE expands to 2.6
Base Case
$12.29
(-53%)
Market implied -50.0%, PE stable at 2.4
Bear Case
$16.71
(-36%)
Severe decline -20.0%, PE contracts to 2.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 7:51 PM ET
Data refreshes hourly during market hours. Next update: 8:51 PM
Data refreshes hourly during market hours. Next update: 8:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |